Why Investors Need More Results From Moderna Vaccine Study

Katherine Ross

Dr. Anthony Fauci, director of the National Institute of Allergies and Infectious Diseases, weighed in on the Moderna vaccine in an interview with NPR Friday, May 22. 

He said, "having looked at the data myself, it is really quite promising." 

That data will be peer-reviewed in the coming weeks, Dr. Fauci said. He also said that multiple vaccine candidates are already making doses before health officials are "completely sure that it works."

Moderna's vaccine candidate, mRNA-1273, was seen as promising following the release of some early test results, sending its stock surging. But the possible vaccine has come under scrutiny in recent days following an article in STAT News where experts noted that the company only released limited data about the vaccine study results.

The drug has now proceeded to a phase 2 trial involving 600 healthy patients, 300 between the ages of 18 and 55, and another 300 aged 55 years and up.

The phase 1 trial that put Moderna on the map tested 45 subjects.

Jeff Marks, senior portfolio analyst with Jim Cramer's Action Alerts PLUS, joined TheStreet's Katherine Ross on Street Lightning to weigh in on what Fauci's comments mean for the vaccine.

Jim Cramer is off on Friday.

You can follow Katherine Ross on Twitter at @byKatherineRoss.

Read more from Katherine Ross here.

Watch More of the Latest Videos from TheStreet and Jim Cramer

 

LIVE WITH JIM CRAMER - WATCH THE REPLAY
Enter your email to register or login. Registration information may be shared with advertising partners in accordance with our Privacy Policy.
Comments

Stock Picks

FEATURED
COMMUNITY